Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced in vivo Performance

Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced in vivo Performance

Antibody-drug conjugates (ADCs) have begun to fulfil their promise as targeted cancer therapeutics with ten clinical approvals to date. As the field matures, much attention has focused upon the key factors required to produce safe and efficacious ADCs. Recently the role that linker-payload reagent d...

Full description

Bibliographic Details
Main Authors: Nick Evans, Ruslan Grygorash, Paul Williams, Andrew Kyle, Terrence Kantner, Ravindra Pathak, XiaoBo Sheng, Fabio Simoes, Hiteshri Makwana, Ricardo Resende, Elena de Juan, Alan Jenkins, David Morris, Aurelie Michelet, Frances Jewitt, Felicity Rudge, Nicolas Camper, Anaïs Manin, William McDowell, Martin Pabst, Antony Godwin, Mark Frigerio, Matthew Bird
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Pharmacology
Subjects:
antibody drug conjugate (ADC)
crown ether
cyclodextrin
in vivo
xenograft
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.764540/full

Similar Items

Similar Items